Add a biography for this author »
The acquisition terms reflect paying a very high valuation multiple and the deal could constrain inorganic investment in the pharma division at a time when the future pipeline of this division is a key concern for investors, following a future integration of Monsanto, Bayer could find itself with a weakened pharma business.
– Asim Rahman
Found on Reuters1 year ago
We cannot accept the Board's decision to deny shareholders any opportunity to vote on it ... Technically the transaction does not require shareholder approval, but an endorsement by shareholders would provide an opportunity to repair market trust in the investment case.
Please enter your email address:
"Asim Rahman Quotes." Quotes.net. STANDS4 LLC, 2017. Web. 22 Nov. 2017. <http://www.quotes.net/authors/Asim+Rahman>.
Your email address:*Required
Pick a user name:*Required
Forgot your password? Retrieve it